NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/18/2025
Back to search
Official data from USPTO
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
02/18/2025
Classification
Registered
Trademark type
Combined
Nice classes
44
Filing date
03/05/2024
Registration date
02/18/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/18/2025
Last transaction
02/18/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
12/28/2022
First use in commerce
12/28/2022
Drawing code
3
Owner type
03
Owner location
New York, NY, US
Examiner
WOLFE, YOUNG J
Law office
N40
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the text "BRIUMVI" in black above the text "UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV" in dark grey with the "B" in "BRIUMVI" partially surrounded by a light blue sphere edged in gold.
Holders and representatives
Holders
TG Therapeutics, Inc.
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 44
Providing health information
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/31/2024
PUBO
PUBLISHED FOR OPPOSITION
12/31/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/25/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/03/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/23/2024
GNRT
NON-FINAL ACTION E-MAILED
09/23/2024
CNRT
NON-FINAL ACTION WRITTEN
09/23/2024
DOCK
ASSIGNED TO EXAMINER
09/18/2024
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/18/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/18/2024
NWAP
NEW APPLICATION ENTERED
03/05/2024
Continuous trademark protection
Get notified about every new filing that threatens BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.